Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Drug Profile

Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Alternative Names: INX-0167; INX-0204; OligoVax; TKM-0167

Latest Information Update: 16 Oct 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Tekmira Pharmaceuticals Corporation
  • Class Antigens; Oligonucleotides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 31 Dec 2012 No development reported - Preclinical for Cancer in Canada (Injection)
  • 02 Jul 2009 Preclinical development in Cancer is ongoing in Canada
  • 23 Jul 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top